Zimmer Biomet (ZBH) Competitors

$82.58 -1.83 (-2.17%)

Closing price 03:59 PM Eastern

Extended Trading

$84.46 +1.89 (+2.28%)

As of 07:49 PM Eastern

ZBH vs. PEN, MDLN, GEHC, PHG, and SOLV

Should you buy Zimmer Biomet stock or one of its competitors? MarketBeat compares Zimmer Biomet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zimmer Biomet include Penumbra (PEN), Medline (MDLN), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and Solventum (SOLV). These companies are all part of the "medical equipment" industry.

How does Zimmer Biomet compare to Penumbra?

Penumbra (NYSE:PEN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Penumbra presently has a consensus target price of $361.33, indicating a potential upside of 12.65%. Zimmer Biomet has a consensus target price of $102.80, indicating a potential upside of 24.49%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

88.9% of Penumbra shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zimmer Biomet had 4 more articles in the media than Penumbra. MarketBeat recorded 6 mentions for Zimmer Biomet and 2 mentions for Penumbra. Penumbra's average media sentiment score of 1.78 beat Zimmer Biomet's score of 1.24 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zimmer Biomet	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has a net margin of 11.76% compared to Zimmer Biomet's net margin of 9.05%. Zimmer Biomet's return on equity of 13.24% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Zimmer Biomet	9.05%	13.24%	7.28%

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.99	$177.69M	$4.34	73.90
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.45

Penumbra has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

Summary

Zimmer Biomet beats Penumbra on 9 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to Medline?

Medline (NASDAQ:MDLN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Medline had 2 more articles in the media than Zimmer Biomet. MarketBeat recorded 8 mentions for Medline and 6 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.24 beat Medline's score of 0.61 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zimmer Biomet has a net margin of 9.05% compared to Medline's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Zimmer Biomet	9.05%	13.24%	7.28%

Medline currently has a consensus price target of $50.85, suggesting a potential upside of 41.87%. Zimmer Biomet has a consensus price target of $102.80, suggesting a potential upside of 24.49%. Given Medline's stronger consensus rating and higher possible upside, equities research analysts plainly believe Medline is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.83
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has lower revenue, but higher earnings than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.66	N/A	N/A	N/A
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.45

Summary

Zimmer Biomet beats Medline on 7 of the 13 factors compared between the two stocks.

How does Zimmer Biomet compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

GE HealthCare Technologies has a net margin of 9.10% compared to Zimmer Biomet's net margin of 9.05%. GE HealthCare Technologies' return on equity of 20.46% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Zimmer Biomet	9.05%	13.24%	7.28%

82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

GE HealthCare Technologies presently has a consensus target price of $80.21, suggesting a potential upside of 25.56%. Zimmer Biomet has a consensus target price of $102.80, suggesting a potential upside of 24.49%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe GE HealthCare Technologies is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.2%. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GE HealthCare Technologies has increased its dividend for 1 consecutive years.

In the previous week, GE HealthCare Technologies had 11 more articles in the media than Zimmer Biomet. MarketBeat recorded 17 mentions for GE HealthCare Technologies and 6 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.24 beat GE HealthCare Technologies' score of 0.79 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Zimmer Biomet	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies has higher revenue and earnings than Zimmer Biomet. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.41	$2.08B	$4.18	15.28
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.45

GE HealthCare Technologies has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Zimmer Biomet on 12 of the 20 factors compared between the two stocks.

How does Zimmer Biomet compare to Koninklijke Philips?

Zimmer Biomet (NYSE:ZBH) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Zimmer Biomet had 5 more articles in the media than Koninklijke Philips. MarketBeat recorded 6 mentions for Zimmer Biomet and 1 mentions for Koninklijke Philips. Zimmer Biomet's average media sentiment score of 1.24 beat Koninklijke Philips' score of 0.93 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.2%. Koninklijke Philips pays an annual dividend of $0.86 per share and has a dividend yield of 3.2%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend. Koninklijke Philips pays out 73.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Zimmer Biomet has a net margin of 9.05% compared to Koninklijke Philips' net margin of 5.49%. Koninklijke Philips' return on equity of 13.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Koninklijke Philips	5.49%	13.51%	5.48%

Zimmer Biomet has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Zimmer Biomet presently has a consensus price target of $102.80, suggesting a potential upside of 24.49%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Koninklijke Philips has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.45
Koninklijke Philips	$20.17B	1.27	$1.01B	$1.17	22.76

Summary

Zimmer Biomet beats Koninklijke Philips on 13 of the 19 factors compared between the two stocks.

How does Zimmer Biomet compare to Solventum?

Zimmer Biomet (NYSE:ZBH) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Zimmer Biomet had 3 more articles in the media than Solventum. MarketBeat recorded 6 mentions for Zimmer Biomet and 3 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.24 beat Solventum's score of -0.15 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zimmer Biomet presently has a consensus price target of $102.80, indicating a potential upside of 24.49%. Solventum has a consensus price target of $84.25, indicating a potential upside of 10.74%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.45
Solventum	$8.33B	1.58	$1.56B	$8.16	9.32

Solventum has a net margin of 17.33% compared to Zimmer Biomet's net margin of 9.05%. Solventum's return on equity of 23.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Solventum	17.33%	23.51%	7.63%

Zimmer Biomet has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Solventum has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Solventum beats Zimmer Biomet on 9 of the 17 factors compared between the two stocks.

Get Zimmer Biomet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBH vs. The Competition

Export

Metric	Zimmer Biomet	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$16.33B	$8.47B	$6.41B	$23.23B
Dividend Yield	1.14%	2.53%	2.75%	4.07%
P/E Ratio	21.45	16.24	21.34	30.90
Price / Sales	1.94	8.34	549.27	24.73
Price / Cash	6.14	17.25	43.13	25.11
Price / Book	1.26	4.06	10.40	4.78
Net Income	$705.20M	$224.05M	$3.56B	$1.07B
7 Day Performance	-3.17%	4.41%	2.95%	1.86%
1 Month Performance	-10.79%	1.32%	2.40%	1.43%
1 Year Performance	-12.30%	0.72%	36.13%	26.97%

Zimmer Biomet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBH Zimmer Biomet	4.6744 of 5 stars	$82.58 -2.2%	$102.80 +24.5%	-9.0%	$16.33B	$8.23B	21.45	17,000	Positive News Dividend Announcement
PEN Penumbra	2.6928 of 5 stars	$326.26 +1.2%	$361.33 +10.8%	+22.2%	$12.68B	$1.40B	75.17	4,700	Positive News
MDLN Medline	4.5042 of 5 stars	$36.02 -0.5%	$50.85 +41.2%	N/A	$47.54B	$28.43B	N/A	43,000
GEHC GE HealthCare Technologies	4.9438 of 5 stars	$61.51 +1.2%	$80.67 +31.1%	-7.2%	$27.64B	$20.63B	14.72	54,000	Insider Trade
PHG Koninklijke Philips	2.9402 of 5 stars	$26.04 +3.2%	N/A	+19.5%	$24.29B	$20.17B	22.32	65,340	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZBH) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, MDLN, GEHC, PHG, and SOLV

How does Zimmer Biomet compare to Penumbra?

Summary

How does Zimmer Biomet compare to Medline?

Summary

How does Zimmer Biomet compare to GE HealthCare Technologies?

Summary

How does Zimmer Biomet compare to Koninklijke Philips?

Summary

How does Zimmer Biomet compare to Solventum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, MDLN, GEHC, PHG, and SOLV

How does Zimmer Biomet compare to Penumbra?

Do analysts prefer PEN or ZBH?

Do institutionals and insiders believe in PEN or ZBH?

Does the media prefer PEN or ZBH?

Is PEN or ZBH more profitable?

Which has better earnings and valuation, PEN or ZBH?

Which has more risk & volatility, PEN or ZBH?

Summary

How does Zimmer Biomet compare to Medline?

Does the media prefer MDLN or ZBH?

Do insiders & institutionals hold more shares of MDLN or ZBH?

Is MDLN or ZBH more profitable?

Do analysts rate MDLN or ZBH?

Which has higher valuation and earnings, MDLN or ZBH?

Summary

How does Zimmer Biomet compare to GE HealthCare Technologies?

Is GEHC or ZBH more profitable?

Do institutionals and insiders hold more shares of GEHC or ZBH?

Do analysts prefer GEHC or ZBH?

Is GEHC or ZBH a better dividend stock?

Does the media favor GEHC or ZBH?

Which has preferable earnings and valuation, GEHC or ZBH?

Which has more volatility & risk, GEHC or ZBH?

Summary

How does Zimmer Biomet compare to Koninklijke Philips?

Does the media favor ZBH or PHG?

Do institutionals & insiders have more ownership in ZBH or PHG?

Is ZBH or PHG a better dividend stock?

Is ZBH or PHG more profitable?

Which has more risk and volatility, ZBH or PHG?

Do analysts prefer ZBH or PHG?

Which has preferable valuation and earnings, ZBH or PHG?

Summary

How does Zimmer Biomet compare to Solventum?

Does the media favor ZBH or SOLV?

Do analysts prefer ZBH or SOLV?

Which has higher earnings and valuation, ZBH or SOLV?

Is ZBH or SOLV more profitable?

Which has more risk & volatility, ZBH or SOLV?

Do insiders & institutionals have more ownership in ZBH or SOLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools